Physician profile
Alejandro Diaz
NPI 1821185869
$100,925.46
in general payments reported to CMS, 2019-2025
42 companies · $76K in 2025
The $76K reported for 2025 was more than what 98% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,172 · 2020: $536 · 2021: $908 · 2022: $2,117 · 2023: $1,825 · 2024: $12K · 2025: $76K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $50K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Food and Beverage: $7,014 · Travel and Lodging: $5,123 · Education: $118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $49,939.48 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $28,000.00 |
| Food and Beverage | $7,013.81 |
| Travel and Lodging | $5,123.06 |
| Education | $117.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $66,642.35 | 2024-2025 | |
| Novo Nordisk INC | $14,150.80 | 2019-2025 | Sogroya, Wegovy |
| Genzyme Corporation | $10,122.51 | 2024 | |
| Eton Pharmaceuticals, INC. | $1,318.83 | 2023-2025 | Alkindi, Khindivi, Increlex |
| Insulet Corporation | $1,211.90 | 2019-2025 | Omnipod |
| Ascendis Pharma Endocrinology INC | $866.65 | 2022-2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $622.06 | 2023-2025 | |
| Tandem Diabetes Care, INC. | $587.74 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Beta Bionics, INC. | $533.95 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Alexion Pharmaceuticals, INC. | $523.29 | 2019-2024 | Strensiq |
| Xeris Pharmaceuticals, INC. | $402.87 | 2020-2025 | Gvoke Hypopen |
| Abbvie INC. | $392.84 | 2019-2025 | Lupron Depot |
| Abbott Laboratories | $322.73 | 2022-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Biomarin Pharmaceutical INC. | $296.95 | 2021-2025 | Voxzogo 1.2mg |
| Lilly USA, LLC | $293.12 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $234.26 | 2019-2022 | |
| Pfizer INC. | $230.51 | 2019-2025 | |
| Dexcom, INC. | $225.52 | 2020-2024 | Dexcom G6 Transmitter |
| Rhythm Pharmaceuticals, INC. | $219.97 | 2021-2025 | Imcivree, Imcivree |
| Amneal Pharmaceuticals LLC | $183.78 | 2019-2024 | Unithroid |
| Lifescan, INC. | $182.13 | 2019-2023 | |
| Mannkind Corporation | $158.50 | 2021-2022 | |
| Azurity Pharmaceuticals, INC. | $155.72 | 2024-2025 | Triptodur |
| Ipsen Biopharmaceuticals, INC | $146.96 | 2019-2023 | Somatuline Depot, Increlex |
| Becton, Dickinson and Company | $109.22 | 2019-2021 | |
| Kyowa Kirin, INC. | $85.69 | 2023-2025 | Crysvita |
| Zealand Pharma US, INC. | $72.79 | 2021-2022 | |
| Tolmar Pharmaceuticals, INC. | $67.69 | 2020-2022 | |
| Amphastar Pharmaceuticals, INC. | $63.27 | 2023-2024 | Baqsimi |
| Ibsa Pharma INC. | $61.28 | 2019-2023 | Tirosint, Licart |
| Aegerion Pharmaceuticals, INC. | $58.38 | 2019 | |
| Arbor Pharmaceuticals, INC. | $56.30 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $56.29 | 2019-2024 | Supprelin |
| Embecta Corp. | $41.82 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Ferring Pharmaceuticals INC. | $39.89 | 2019-2020 | |
| Amryt Pharma Holdings LTD | $39.48 | 2021 | |
| Medtronic, INC. | $32.64 | 2021-2024 | Mycarelink |
| Mirum Pharmaceuticals, INC. | $27.65 | 2025 | Cholbam, Livmarli, Chenodal |
| Dermira, INC. | $24.85 | 2020 | |
| Companion Medical, INC. | $21.20 | 2020 | |
| Sequel Med Tech, LLC | $20.65 | 2025 | Twiist |
| Endo USA, INC. | $20.43 | 2024 | Supprelin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alejandro Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.